Abstract | BACKGROUND: OBJECTIVE: DESIGN: Double-blind, randomized, placebo-controlled trial. SETTING: University teaching hospital. PATIENTS: INTERVENTION: MEASUREMENTS: Bone mineral densities of the total body, lumbar spine, proximal femur (femoral neck, Ward triangle, trochanter), and proximal forearm were measured every 6 months using dual-energy x-ray absorptiometry. Biochemical indices of bone turnover and calcium metabolism were measured at baseline, 6 months, and 2 years. RESULTS: In the placebo group, bone mineral densities of the total body and the proximal forearm decreased significantly from baseline (mean +/- SE, -2.3% +/- 0.7% [p = 0.005] and -3.5% +/- 1.2% [p = 0.01], respectively). At the other sites, bone mineral density also tended to decline. In the hormone replacement therapy group, bone mineral density increased from baseline in the total body (1.3% +/- 0.4%; P = 0.004), lumbar spine (5.2% +/- 1.4%; p = 0.002), and femoral neck (3.4% +/- 1.5%; p = 0.05). The between-group differences in bone mineral density at the end of the study ranged from 3.6% to 6.6% and were significant at all sites (P > 0.001 and P < 0.05) except for the Ward triangle (p = 0.06). In the hormone replacement therapy group, serum alkaline phosphatase levels decreased by 22% (p = 0.0004 compared with baseline), urinary hydroxyproline excretion decreased by 42% (p = 0.0004), urinary N-telopeptide excretion decreased by 54% (p = 0.001), and urinary calcium excretion decreased by 45% (p = 0.007). Hormone replacement therapy did not change levels of serum ionized calcium or intact parathyroid hormone. CONCLUSIONS:
|
Authors | A B Grey, J P Stapleton, M C Evans, M A Tatnell, I R Reid |
Journal | Annals of internal medicine
(Ann Intern Med)
Vol. 125
Issue 5
Pg. 360-8
(Sep 01 1996)
ISSN: 0003-4819 [Print] United States |
PMID | 8702086
(Publication Type: Clinical Trial, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Estrogens, Conjugated (USP)
- Progesterone Congeners
- Medroxyprogesterone Acetate
- Calcium
|
Topics |
- Aged
- Bone Density
(drug effects)
- Bone Diseases, Metabolic
(complications, drug therapy, metabolism, physiopathology)
- Calcium
(metabolism)
- Double-Blind Method
- Drug Therapy, Combination
- Estrogen Replacement Therapy
- Estrogens, Conjugated (USP)
(adverse effects, pharmacology, therapeutic use)
- Female
- Humans
- Hyperparathyroidism
(complications)
- Medroxyprogesterone Acetate
(adverse effects, therapeutic use)
- Middle Aged
- Progesterone Congeners
(adverse effects, therapeutic use)
|
|
Join CureHunter, for free Research Interface BASIC access!
Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease.
Find out why thousands of doctors, pharma researchers and patient activists
around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!
|